Vaderis Therapeutics
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
$152MSeries B
Role not disclosedPA
Perceptive Advisors
Activity from announced rounds
Activity in this selectionEurope
Perceptive Advisors is the healthcare investment manager named in Superluminal’s financing and retained company records.
Recorded funding activity
Superluminal develops small-molecule medicines using structural and experimental methods. Vaderis develops an oral treatment for hereditary hemorrhagic telangiectasia, while Imperative develops thromboembolic interventions. The manager remains separate from the Xontogeny venture arm.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $152M 1 disclosed · full round size, not this investor’s share